MS finding supports T-cell targeting; ALS gene a boost for antioxidants
MS finding supports T-cell targeting
The discovery of the dominant immune response that causes multiple sclerosis, announced last week by researchers at Neurocrine Biosciences Inc. and Stanford University, is validating an approach taken by several biotech companies.
In their article published in Nature, the Stanford group led by Lawrence Steinman identified the specific T-lymphocytes that attack a fragment of myelin basic protein (MBP), a component of the myelin sheath surrounding nerve fibers.
This is the first time anyone has completely sequenced the T-cells in the lesions of MS patients, Steinman told BioCentury. "What we found is that 40 percent of the T-cells in the lesions are the same as in animal